Merck Sharp & Dohme LLC v. Surrozen Operating, Inc. et al.

PGR2026-00027

Merck has filed a post‑grant review petition challenging U.S. Patent 12,297,278 covering broad tetravalent Wnt‑surrogate antibodies. The petition asserts lack of written description, enablement, indefiniteness, and anticipation by the Garcia publication.

Jurisdiction
US PTAB
Case Number
PGR2026-00027
Filing Date
2 December 2026
Status
ok

Related Cases

patentIPR2026-00098

Google LLCvsSecure Communication Technologies, LLC

Google has filed an IPR petition seeking to invalidate Secure Communication Technologies' ’736 patent covering server‑mediated data exchange between wireless devices, relying on Eagle and Mgrdechian prior art.

patentIPR2025-00404

Ericsson Inc et al.vsHEADWATER PARTNERS II LLC

Ericsson Inc. successfully petitioned to invalidate key claims of Headwater Partners II LLC's patent related to wireless backhaul systems. The PTAB found a reasonable likelihood that the claims are unpatentable based on obviousness and anticipation over prior art (Ishii and Sfar).

patentIPR2024-00625

Merck Sharp & Dohme LLC et al.vsThe Johns Hopkins University

Merck Sharp & Dohme LLC successfully petitioned to institute IPR proceedings against The Johns Hopkins University regarding anti-cancer immunotherapy claims. The Board found sufficient evidence that the MSI-H Study Record anticipates key claims, warranting further trial on grounds of anticipation and obviousness.

patentIPR2024-00644

AT&T Corp et al.vsDaingean Technologies Ltd.

The PTAB denied institution of IPR against Daingean Technologies' patent, finding that the petitioner failed to prove its sole prior art reference (R2-1702708) was a publicly accessible printed publication.

patentIPR2024-00639

Under Armour, Inc.vsAthalonz, LLC

Under Armour successfully petitioned the PTAB to institute IPR on claims related to athletic footwear sole technology, arguing they are obvious under 35 U.S.C. § 103. The Board granted institution, adopting key claim constructions and recognizing the validity of multiple prior art combinations cited by the Petitioner.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call